---
$id: https://graph.org.ai/products/commodity/51263006
$type: Product
source: UNSPSC
code: "51263006"
title: "Terazosin"
class: "51263000"
classTitle: "Adrenergic blocking agent piperazines"
family: "51260000"
familyTitle: "Adrenergic blocking agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Terazosin

**UNSPSC Code**: 51263006
**Class**: [Adrenergic blocking agent piperazines](Adrenergic blocking agent piperazines.mdx)
**Family**: [Adrenergic blocking agents](../Adrenergic blocking agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8L5014XET7, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine but generally known as terazosin, which bears US NIH Compound Identifier 5401. European Medicines Agency schedules Terazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10907MIG. The term TERAZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules terazosin in its Anatomical Therapeutic Chemical (ATC) Classification. TERAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule terazosin under HS 29349990 and SITC 51579. As of Q4 2014, TERAZOSIN remains the US FDA Preferred Term for this commodity. Terazosin bears US NLM identifiers UMLS ID C0076107 and NCI Concept Code C61964. SMILES: O1C(CCC1)C(=O)N1CCN(CC1)C1NC2C(C(N1)N)CC(OC)C(OC)C2.

